Skip to main content

Table 2 Top ten samples across the 21,504 analyzed in this paper in order of descending junction inclusion ratio D, as defined in the table

From: Human splicing diversity and the extent of unannotated splice junctions across human RNA-seq samples on the Sequence Read Archive

Rank Sample (i.e., run) Project Description of sample Junction Junction Total junction D=(B-A)/C
     coverage A for ALK coverage B for ALK coverage C  
     exons 1–19 exons 20–29 across ALK  
1 SRR545713 SRP007461 NHEM.f_M2: normal human 0 139 139 1
    melanocyte     
1 SRR396804 SRP010166 Non-small cell lung 0 172 172 1
    adenocarcinoma     
1 SRR620100 SRP017262 Leukemia 0 108 108 1
4 SRR1289650 SRP042031 Macrophage 1 85 86 0.976
5 SRR1289651 SRP042031 Macrophage cultured 1 77 78 0.974
    with fibroblast     
6 SRR545716 SRP007461 NHEM_M2: normal human 2 94 96 0.958
    melanocyte     
7 SRR628586 SRP017413 Uveal melanoma 12 111 123 0.805
8 DRR016705 DRP001919 H2228, an EML4-ALK-expressing 38 285 333 0.765
    lung adenocarcinoma cell line     
9 SRR545714 SRP007461 NHEM.f_M2: normal human 14 63 77 0.636
    melanocyte     
10 ERR532612 ERP006077 Prostate tumor 16 53 69 0.536
  1. D essentially measures the difference in expression between junctions across ALK exons 1–19 and junctions across ALK exons 20–29. Values of D close to 1 may point toward expression of ALK ATI, a novel transcript variant of ALK recently identified in [29] across several cancers but not normal cells. Several cancer samples appear, but interestingly, normal cell samples also appear, including melanocytes and macrophages